Introduction {#s1}
============

The most widely accepted definition of mental retardation (MD) relays on impairment of both cognitive and social adaptive functions [@pone.0103117-Wu1]. Recently, the terminology MD had been replaced with DD/ID referring to patients affected with developmental delay/intellectual disability. Epidemiological data suggests that DD/ID affect up to 3% of the worldwide population and it may concur with or without multiple congenital anomalies (MCA) and also can be found in patients with no phenotypic traits [@pone.0103117-Pani1]-[@pone.0103117-Galasso1].

ID is a complex, variable, and heterogeneous disorder, representing a disabling condition diagnosed worldwide, most commonly associated with neuropsychiatric disorder in children and adolescents [@pone.0103117-Wu1]. ID is a condition characterized by the impairment of cognitive and adaptive skills that begins before the age of 18 years [@pone.0103117-Millichap1], [@pone.0103117-Galasso1]. The etiological diagnosis of ID remains a clinical challenge. For this particular trait, genetic and environmental factor may play an important role in its pathogenesis [@pone.0103117-Wu1].

ID has a major impact on the life of the affected person, as well as his or her family and society. Thus, a specific diagnosis allows for a better understanding of the etiology of ID and patient clinical management, prognosis, and risk of recurrence [@pone.0103117-Pfundt1]. Microscopic chromosomal abnormalities and well-characterized genetic conditions are the most common causes of ID, accounting for up to 40% of the observed cases. G-banding karyotyping is the standard genetic test for the laboratory investigation of ID and definitive diagnose is found in about 28% of ID cases following conventional karyotyping. Additionally, microscopic chromosome aberrations are found in association with up to 35% of the cases when using molecular cytogenetic tools, such as FISH, CGH, and MLPA that have contributed to increase the resolution of chromosomal rearrangement detection. However, about 50% of the molecular etiology of ID remains unknown. Therefore, at least half of children with ID remains without a diagnosis and poses a relevant clinical challenge [@pone.0103117-Pani1], [@pone.0103117-Flore1], [@pone.0103117-Rauch1].

Array-based chromosomal analyses have made it possible to identify putatively pathogenic copy number variation (CNVs) that could explain the molecular etiology of ID. Current estimates have indicated that approximately 15% to 20% of ID cases are due to submicroscopic CNVs [@pone.0103117-Wu1], [@pone.0103117-Gijsbers1]--[@pone.0103117-Miller1]. Recently, Chromosomal Microarray Analysis (CMA) using high density SNP probes increased genomic resolution and improved the detection of pathogenic microdeletions and microduplications. Moreover, the detection of cryptic genomic imbalances associated with apparently balanced chromosome rearrangements can also be detected when using CMA [@pone.0103117-Cooper1]. Nowadays, CMA has become the genetic test of choice to detect CNVs in patients with developmental disabilities and has increased the diagnostic yield for global developmental delay, intellectual disability, autism, and epilepsy [@pone.0103117-McGillivray1], [@pone.0103117-Riggs1].

From 2010 through 2012, several patients with initial diagnosis of ID were referred to our laboratory. Herein, we attempt to establish an explanation for the phenotype of 15 patients with ID using a high-density resolution SNP microarray to determine clinical relevant CNVs over the entire genome. We report that 10/15 patients showed deletions and/or duplications that could explain patients\' phenotype. To our knowledge, this is the first report on genomic rearrangements and ID in a cohort from Central Brazil, representing a population not yet screened by microarray technology.

The aim of the current study was to identify possible submicroscopic genomic alterations using a high-density chromosomal microarray in a retrospective cohort of patients with otherwise undiagnosable intellectual disabilities referred by doctors from the public health system in Central Brazil.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

All participants had ID without etiological diagnosis after undergoing a thorough clinical evaluation. Assistant physicians from the Goiás state public health system referred each patient to our genetic service at both the Laboratory of Human Cytogenetic and Molecular Genetics and the Biology Department at Pontifical Catholic University in Central Brazil. The study population was comprised of a retrospective cohort which included 305 probands with clinical diagnosis of ID with our without multiple congenital anomalies (MCA) assisted at the Laboratory from 2010 to 2012. From those, 182 patients had visible chromosome aberrations from which accurate and definite diagnoses were possible. Of the remaining 123 cases, we contacted every family in order to explain about CMA as a new available genetic test potentially useful to explain the ID of the proband and also to offer the test to the family. From the remaining cases, 3 children died, 39 children missed one or both biological parents, for 44 cases the follow up were not successful due to address/telephone changes and additional information unavailability to contact the families, and 22 families were invited to participate in study. Based on an autonomous voluntary decision, only 15 families joined the task and signed an ethical informed consent if the cases adhered to the following inclusion criteria: (1) Normal G-banding karyotyping; (2) PCR negative results for *FMR1* gene mutations; (3) No family history of DD/ID; (4) No medical history of hypoxia, intoxication, infection or cranial trauma; (5) No history of perinatal brain injury; (6) Probands born to intellectually normal non-consanguineous parents; (7) Availability of biological parents to participate in the study. Due to cognitive limitations and/or individual age, probands were not able to make the decision to enroll themselves in the study. Thus, their parents or guardians signed the informed consent forms approved by the Ethics Committee on Human Research at the Pontifical Catholic University of Goiás (CEP-PUC/GO), under the protocol number 1721/2011.

Biological Samples {#s2b}
------------------

For each proband and their biological parents, a total of 5 mL of peripheral blood was drawn using a standard vacuum extraction blood-collecting system containing EDTA. Genomic DNA was isolated from whole blood using QIAamp DNA Mini kit (Qiagen, Germany), following the manufacturer\'s instructions. Conventional cell cultures, harvesting, and G-banding at the level of 550 bands were performed for all patients following standardized procedures [@pone.0103117-Verma1]. Chromosome observations were performed using a Zeiss Axioscope (Göttingen, Germany) and analyses using IKAROS (Metasystems Corporation, Altlussheim, Germany).

CMA: Chromosomal Microarray Analysis {#s2c}
------------------------------------

The analyses were carried out on probands and their biological parents in order to establish the origin of DNA rearrangements if *de novo* or inherited. A total of 250 ng of isolated DNA for each sample was digested with NspI, ligated, PCR amplified and purified, fragmented, biotin-labeled, and hybridized to be used in a GeneChip HD CytoScan Array (Affymetrix, Santa Clara, USA), following strictly the manufacturer\'s protocol to identify potentially pathogenic CNVs. The array was designed specifically for cytogenetic diagnose, including ∼2,7 million clinically relevant CNVs based on 743,304 SNP, and \>1.9 million non-polymorphic probes covering the whole human genome. CEL files obtained by scanning the arrays were analyzed using the Chromosome Analysis Suite (ChAS) software (Affymetrix, Santa Clara, USA) in order to establish the genotypes. Genomic gains and losses that affected a minimum of 50 and 25 markers, respectively, in a 100 kb length were initially considered to determine the relevance of duplications and deletions. When using ChaS, CNVs boundaries were putatively inferred based on probe density. The two major quality control metrics for the GeneChip HD array were the Median Absolute Pairwise Difference (MAPD) and SNP-QC scores that apply to copy number and SNP probes, respectively. For our diagnostic setting, we applied the parameters ≤0.25 for MAPD and ≥15 for SNP-QC.

CNV classification {#s2d}
------------------

CNVs were classified according to their nature, based on [@pone.0103117-Pani1], [@pone.0103117-Miller1], [@pone.0103117-Battaglia1]. In summary, the CNVs found in each patient and their biological parents were compared with genomic variants in public databases, including Database of Genomic Variants (DGV), Database of Chromosomal Imbalance and Phenotype in Humans using Ensemble Resources (DECIPHER), and CytoScan HD Array Database. CNVs were classified as pathogenic, likely pathogenic, and of unknown clinical significance, according to [@pone.0103117-Miller1], [@pone.0103117-Battaglia1]. Benign CNVs were filtered out from subsequent analysis.

Results {#s3}
=======

Herein, we report the results for CMA of 15 families, including proband and their biological parents. The cohort was comprised of 6 males and 9 females with intellectual disability with age ranging from 2 to 25 years old, and their progenitors with age at conception ranging from 21 to 47 years old. For all probands, G-banding karyotypes showed no visible alterations (46 XX or 46XY). The clinical and molecular features of patients were included in [Table 1](#pone-0103117-t001){ref-type="table"}.

10.1371/journal.pone.0103117.t001

###### Clinical and molecular features of 15 probands with intellectual disability screened with high-resolution CMA technology in Goás (Brazil).

![](pone.0103117.t001){#pone-0103117-t001-1}

  Case    Clinical features[\*](#nt101){ref-type="table-fn"}   Age (yo)   Sex   CNV    Mosaic (%)   Cytoband    Size (Mb)   Marker Count           Microarray nomenclature           Number of genes                                                      Selected OMIN Morbid Genes\*\*                                                         Origin       Interpretation
  ------ ---------------------------------------------------- ---------- ----- ------ ------------ ----------- ----------- -------------- ----------------------------------------- ----------------- -------------------------------------------------------------------------------------------------------------------------------------- --------------- ----------------
  001                          GDD, SS                            9        F    NAF                                                                                                                                                                                                                                                                           Negative\*\*\*
  002                            GDD                              11       M    Loss                 1p13.3       0.13           54          1p13.3(108,726,456--108,853,796)x1             2                                                                        *NBPF4*                                                                    *de novo*          UCS
                                                                                Gain                  1q44        0.53          600           1q44(246,174,090--246,702,392)x3              2                                                                        *SMYD3*                                                                  Inherited mat        UCS
                                                                                Gain                  1q44        0.34          348           1q44(247,080,457--247,416,825)x3              8                                                                    *AHCTF1, ZNF124*                                                             Inherited mat        UCS
                                                                                Gain       50        17p11.2      3.68          4151          17p11.2(16,769,800--20,446,820)x3            64          *COPS3, SMCR9, RAI1, SMCR5, TOM1L2, LRRC48, ATPAF2, DRG2, MYO15A, ALKBH5, FLII, SMCR8, SHMT1, USP32P2, CCDC144B, B9D1,MFAP4, RNF112*     *de novo*       Pathogenic
  003                            GDD                              17       M    Gain                 7q31.32      0.67          785          7q31.32(122,366,542--123,036,250)x3            3                                                                        *CADPS2*                                                                 Inherited pat        UCS
  004                        GDD, SS, MS                          2        M    Gain                12q13.13.     0.52          396        12q13.13q13.2(54,462,464--54,980,062)x3         19                                                                        *SMUG1*                                                                    *de novo*          UCS
                                                                                Loss                 14q11.2      0.21          298           14q11.2(22,732,618--22,941,375)x1             0                                                                                                                                                 Inherited mat        UCS
  005                          GDD, MS                            9        M    NAF                                                                                                                                                                                                                                                                              Negative
  006                            GDD                              11       F    Loss                 Xq27.3       4.18         10150        Xq27.3q28(144,580,614--148,757,072)x1          33                                                         *CXorf1/TMEM257, FMR1, TMEM185A, IDS*                                                     *de novo*       Pathogenic
  007                        GDD, MS, MCA                         4        F    Loss                 7q31.1       0.39          265          7q31.1(110,923,434--111,310,159)x1             1                                                                        *IMMP2L*                                                                 Inherited mat         LP
                                                                                Loss       30       18p11.32      1.23          1400           18p11.32(136,226--1,369,804)x1              11                                                                       *ADCYAP1*                                                                   *de novo*           LP
                                                                                Gain       40        18q11.1      5.80          2125       18q11.1q23(18,608,373--78,014,123)x2--3                                                                            *18q Partial Trissomy*                                                            *de novo*       Pathogenic
                                                                                Gain                 Xp22.33      25.72        31456         Xp22.33p21.3(168,546--25,887,307)x3           147                                                *NLGN4X, AP1S2, NHS, CDKL5, RPS6KA3, MBTPS2, SMS, ARX*                                            *de novo*       Pathogenic
  008                          GDD, SS                            25       F    NAF                                                                                                                                                                                                                                                                              Negative
  009                        GDD, MS, ALS                         10       F    NAF                                                                                                                                                                                                                                                                              Negative
  010                          GDD, MS                            9        F    NAF                                                                                                                                                                                                                                                                              Negative
  011                        GDD, BD, MS                          8        F    Loss                 1p31.3       10.89        10080        1p31.3p31.1(68,693,129--79,580,916)x1          49                                                                         *AK5*                                                                     *de novo*           LP
  012                            GDD                              6        M    Loss                 14q11.2      0.34          580           14q11.2(22,599,355--22,943,573)x1             0                                                                                                                                                   *de novo*          UCS
  014                          GDD, SS                            14       M    Loss                 14q11.2      0.14          188           14q11.2(22,799,790--22,944,507)x1             0                                                                                                                                                 Inherited mat        UCS
                                                                                Gain                22q11.23      0.34          140        22q11.23q12.1(25,656,237--25,994,326)x3          4                                                                                                                                                 Inherited mat         LP
  015                          GDD, MS                            8        F    Loss                  15q23       0.14          180            15q23(71,537,904--71,673,921)x1              1                                                                                                                                                 Inherited mat        UCS
                                                                                Gain                  Xq28        0.14          344           Xq28(152,720,466--152,860,955)x3              4                                                                    *ATP2B3, FAM58A*                                                             Inherited mat        UCS
  016                          GDD, MS                            5        F    NAF                                                                                                                                                                                                                                                                              Negative

\* SS = Short Stature; GDD = Global Developmental Delay; MS = Multiple Stigmas, MCA = Multiple Congential Anomalies, ALS =  Autism Like Symptoms; BD = Behavior Disorders; Disturbance of brain electrical activity; \*\* Genes related to ID/Autsm; \*\*\* Negative means that no genomic rearrangements were found using CMA; yo = years old; NAF = No Alterations Found; UCS = Unknown Clinical Significance; LP = Likely Pathogenic.

We found a total of 18 CNVs that were identified in 9/15 (60%) patients. The CNV set was equally distributed, 9/18 (50%) and 9/18 (50%) were duplications and deletions, respectively. In six cases (40%), no chromosome rearrangement was observed. Moreover, molecular karyotyping of all 30 progenitors included in our cohort showed no evidence of chromosome rearrangements. Pathogenic and likely pathogenic CNVs were classified based on their size, gene content, and previously reported cases of potential involvement with pathogenic mechanism in human and animal models. In our cohort, pathogenic CNVs represented about 22% (4/18) of all observed rearrangements and were associated with chromosomes 17, 18, and X ([Figure 1](#pone-0103117-g001){ref-type="fig"} and [Figure 2](#pone-0103117-g002){ref-type="fig"}), involving genes that were related to the formation and/or maintenance of the central nervous system. Also, pathogenic CNVs included morbid genes from OMIM (Online Mendelian Inheritance in Man). Moreover, all pathogenic CNVs in this study had a *de novo* origin. Four out of 18 (22%) CNVs were classified as likely pathogenic and 10/18 (56%) CNVs were classified as of unknown clinical significance because they overlapped by more than 90% of the CNVs observed in the databases of normal control groups. Inherited and *de novo* CNVs were equally distributed. However, 8/18 (45%) of CNVs were maternally inherited.

![CNVs pathogenics from probands 002 and 006.\
(**A**) CMA from patient 002 showing a 3.677 Mb microduplication at 17p11.2 involving 64 genes. (**B**) CMA from patient 006 showing Xq27.3-q28 microduplication with 4.176 Mb that includes 4 genes related to intellectual disability.](pone.0103117.g001){#pone-0103117-g001}

![Genomic imbalances from proband 007.\
(**A**) 18p11.32 microdeletion (red line) and the 18q partial trisomy in mosaicismo (light blue line) (**B**) *de novo* microduplication at Xp22.33-Xp21.3 (blue line) that involves 147 genes.](pone.0103117.g002){#pone-0103117-g002}

Discussion {#s4}
==========

The correct diagnosis of a neurological disorder is crucial for predicting the probands\' clinical follow up, to establish accurate prognostic, and to provide adequate genetic counseling. CMA technology is a relatively new strategy useful as an additional tool for genetic diagnosis. The method has been recommended as the first-tier diagnostic test for patients with global developmental delay, intellectual disability, autism spectrum disorders, and multiple congenital anomalies [@pone.0103117-Riggs1].

In the current study, high-resolution CMA was carried out on 15 patients with ID, and relevant CNVs were found in 9 patients. From those, it was possible to propose the etiology of intellectual disability for 3 patients (20%), which is consistent with other studies that have used this or similar technologies, and reported improving the diagnostic yield up to 10--25% [@pone.0103117-Miller1], [@pone.0103117-Battaglia1]--[@pone.0103117-Howell1].

No changes in copy number were observed in six (40%) patients. Thus, it was not possible to suggest a genetic cause for the ID and high-resolution CMA was not useful to diagnose these cases. The possibility of testing these individuals with more sensitive or specific genomic technologies, such as next-generation exome sequencing could be a fruitful diagnostic approach in order to identify gene mutations that may be causing the observed phenotype [@pone.0103117-Lalonde1]--[@pone.0103117-Toscano1]. Moreover, ID is a polygenic complex and heterogeneous multifactorial trait, which remains a diagnostic challenge for human geneticists and heavily affected by environmental factors.

We identified 4 (22%) pathogenic CNVs, including chromosomal imbalances associated with 17p11.2, Xq27.3, 18q11.1 and Xp22.33. Case 2 was a boy who presented a *de novo* microduplication at 17p11.2. Interestingly, the log ratio probe intensity on this region was compatible with a mosaic duplication affecting about 50% of cells. The region has been implicated in the Potocki-Lupski Syndrome (MIM 610883) [@pone.0103117-Potocki1], [@pone.0103117-TreadwellDeering1]. Additionally, microdeletion of this region has been associated with Smith-Magenis Syndrome (MIM 182290). Gain or loss of genomic material on chromosome band 17p11.2 inevitably leads to phenotypes that include ID as a relevant trait [@pone.0103117-Dahl1].

Patient 6 was a girl who showed a *de novo* microdeletion of about 4.2 Mb at Xq27.3, including the region of the Fragile X Syndrome (FXS). CGG trinucleotide repeats expansions are the most common cause of FXS. However, less frequently point mutations and partial or full deletions of the *FMR1* gene also cause the FXS. To date, only 10 female index patients with deletions harboring *FMR1* have been reported. Moreover, the severity of the phenotype for females with *FMR1* deletions correlates with their X-chromosome inactivation [@pone.0103117-Dahl1]--[@pone.0103117-Zink1].

Case 7 was a girl severely affected with multiple congenital abnormalities and intense dysmorphology. This proband, presented a *de novo* 18q partial trisomy with 40% mosaicism identified by CMA. Furthermore, we analyzed 100 metaphase spreads and we observed the duplication of 18q in a mosaic state in 45% of the cells. We also found that the break point called by the CMAs was overestimated due to an array of small duplications upstream from the real duplication site, which created an artificially large partial trisomy of 18. Also we observed in CMA a small deletion in the terminal region stating at 18p11.32. The karyotyping reveled that in fact there was a duplication of a distal region of 18q starting at 18q22.3, resulting in a segment of 5.8 Mb. The chromosome images revealed that the two breakpoints alongside the chromosome 18 created a rearranged chromosome, which included a pericentric inversion of that DNA segment. As a result, there was a loss of the terminal end of 18q, including its centromere. Although CMA was robust to identify the deletion and the duplication, it was not able to indicate the chromosomal inversion. Moreover, especial care must be devoted to the callings made CMA in order to avoid overestimation of the size of the segments involved in gain or loss of chromosome material.

Full trisomy 18 is known to cause Edward\'s Syndrome. However, partial trisomy of chromosome 18, especially involving 18q, has long been reported to cause peculiar phenotypes that show cognitive impairment, varying from a milder to a more severe form, with or without internal malformation. The extent of the partial trisomy and the level of the mosaic state affect the odds of patients\' survival [@pone.0103117-Freson1]--[@pone.0103117-BoghosianSell1]. Interstitial duplications of the short arm of the X chromosome have been rarely described [@pone.0103117-Daoud1]. In Patient 7, we also observed a *de novo* microduplication at Xp22.33-Xp21.3 harboring 8 OMIM morbid genes ([Table 1](#pone-0103117-t001){ref-type="table"}) that have been described in association with ID [@pone.0103117-Daoud1]--[@pone.0103117-Das1].

The CNVs designated as likely pathogenic comprise of 22% of our data. They were called likely pathogenic because they harbor genes having well-established association with abnormal phenotypes. Moreover, their genic content has been implicated in the process of neurological development (42), as mediators of neuroendocrine stress responses (51), to be expressed exclusively in the brain (64). However, none of the genes observed in the likely pathogenic CNVs was yet directly related to ID. We also observed a maternally inherited region which was involved with Chromosome 22q11.2 Duplication Syndrome (MIM 608363) [@pone.0103117-Brunet1]. This region is also found deleted in the DiGeorge Syndrome (MIM 188400) and Emanuel Syndrome (MIM 609029). Both syndromes are characterized by multiple congenital anomalies, significant developmental delay, and mental retardation [@pone.0103117-Carter1].

At the case 15, despite the location of *ATP2B3* and *FAM58A* genes in Xq28, this region has not yet been implicated in ID *per se*. *ATP2B3* gene encodes a calcium-transporting ATPase predominantly expressed in the brain, and mutations in the gene have been associated with increased plasmatic concentrations of aldosterone and reduced plasmatic potassium [@pone.0103117-Beuschlein1]. Moreover, base substitution in *ATP2B3* identified by exome sequencing in a family with X-linked congenital ataxia (XCA) indicated the importance of calcium homeostasis in neurons. Nevertheless, the affected persons present neither mental retardation nor pyramidal tract involvement at their neurological examinations [@pone.0103117-Bertini1]. On the other hand, mutations in *FAM58A* cause an X-linked dominant disorder known as STAR Syndrome (MIM 300707). This syndrome presents facial dimorphism, toe syndactyly, telecanthus, anogenital and renal malformations [@pone.0103117-Unger1]. Nevertheless, patients with STAR Syndrome do not show ID.

The proportion of CNVs classified as of unknown clinical significance was high (56%) in our study. According to researches, the ability to detect CNVs has far outpaced our ability to understand their role in a disease [@pone.0103117-Zilina1]. Inheritance studies are the primary strategy recommended to estimate the role of such CNVs in pathogenicity. Nevertheless, it is often imprudent to attribute clinical significance to a CNV based solely on its inheritance pattern as a growing number of CNVs show an incomplete penetrance and also because de novo CNVs may represent benign variants. The clinical and genetic interpretation of the data acquired by CMA technologies still remains a challenge and often require further specific investigations [@pone.0103117-Kearney1]. To confirm the pathogenicity of a CNV requires studies designed to understand the causative relation between the genomic imbalances to the investigated disease. The genetic interpretation and clinical relevance of the data acquired by CMA technologies remain a challenge. Primarily due to the deleterious effects caused by small genomic variations, such as point mutations, further influenced by reduced penetrance, variable expressivity, and gene dosage [@pone.0103117-Zanni1].

Despite the small size of the cohort screened in the current study, here we report the nature of CNVs in patients from Central Brazil, representing a population not yet screened by microarray technologies. Tests based on microarray technologies are relatively new and are likely to continue to evolve in the coming years. For both, patients and families, it is very important to establish a diagnosis for ID. Furthermore, the diagnosis has to be linked to genetic counseling to ensure that parent\'s views and preferences are taken into account, following a non-directive approach. The results of our study helped the families and their assistant physicians to reach an accurate diagnosis bringing closure to their post-natal search for an explanation regarding the ID observed in the family.
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